Valneva Se ADR (VALN)

$8.90 +0.06 (0.68%)
Market Cap 765.21M
Revenue (ttm) 183.50M
Net Income (ttm) -13.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7.22%
Debt to Equity Ratio 1.11
Volume 8,100
Avg Vol 39,048
Day's Range N/A - N/A
Shares Out 85.98M
Stochastic %K 32%
Beta 1.83
Analysts Strong Sell
Price Target $12.89

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 2 28 07 37 10
Fax: 33 2 28 07 37 11
Website: valneva.com
Address:
6 rue Alain Bombard, Saint-Herblain, France
SuperGreenToday
SuperGreenToday Dec. 4 at 11:10 PM
$VALN
0 · Reply
Creisi
Creisi Dec. 3 at 3:07 PM
$VALN It's from France and positive news on foreign traded stocks simply don't hit the headlines in the USA like USA based companies do. Had Pfizer released this data, it would have exploded. Valneva need to do their Press Releases in partnership with Pfizer and the response will be 5x better. 45% of the world's investment market is the USA. Focus your PR news releases on the USA market and the impact is magnified. I've been around for over 30 years and have seen this scenario a 1000+ times for non USA companies.
0 · Reply
buzzkiller
buzzkiller Dec. 3 at 2:10 PM
$VALN that the market is continually rejecting any positive sp momentum tells me there is some sort of unspoken issue with this co. -- any guesses?
1 · Reply
BluePeakCapital
BluePeakCapital Dec. 2 at 2:41 PM
$VALN
0 · Reply
ajmore
ajmore Dec. 2 at 10:15 AM
$VALN pfizer's set back on the covid front due to myocarditis will leave them with no option but to acquire valneva for the covid vaccine. just a reminder, novavax vlp vaccine had issues with myocarditis too!
0 · Reply
buzzkiller
buzzkiller Dec. 1 at 11:07 AM
$VALN high school kids in Atlanta beating this company..
0 · Reply
Creisi
Creisi Nov. 30 at 7:37 PM
$VALN This vaccine is also effective against the Lone Star Tick which turns eating meat into a death sentence... this tick is also becoming prominent in the Southwest and as far up the coast as Maine... 2 weeks ago a NYC resident died after being bitten by a Lone Star Tick and then eating a hamburger. The market opportunity for a Lyme Disease Vaccine is a game changer and USA sales projections are grossly underestimated by analysts. Anyone that does anything outside is going to get this vaccine... it makes no sense not to. Virtually zero side effects and extremely protective. With Pfizer making a BLA submission in 2026 to market the Vaccine on VALNEVA's behalf, this little vaccine company will be bought by Pfizer by October 2026 or will report huge earnings by 2027 thrusting this stock price will into the $50-60 range either way.
1 · Reply
Siuolman58
Siuolman58 Nov. 29 at 9:44 AM
$VALN https://share.google/L2fPl3T5beSVlnffY
0 · Reply
Creisi
Creisi Nov. 28 at 1:14 PM
$VALN On track for the Lyme Disease Vaccine BLA in 2026 according to news reports in partnership with Pfizer. Expected $200,000,000 Annual Royaly Payments from Pfizer from the Lyme Vaccine alone. Strong Pfizer Buy Out rumours as Valneva consolidates operations in Lyon, France.
0 · Reply
Mac24Daddy
Mac24Daddy Nov. 26 at 4:04 PM
$VALN caution. Still trying to recoup from England, pulling the Covid vaccine and then the recent FDA removal of the next vaccine and now this. I’m really cautious at this point every time we look for a break out something comes up and throws a wrench in the works. Understandably, we can’t protect the outcomes, but this would be three for three if it hits the south side of where it’s supposed to go.
1 · Reply
Latest News on VALN
VALNEVA Declaration of shares and voting rights: November 30, 2025

Dec 5, 2025, 12:34 PM EST - 1 day ago

VALNEVA Declaration of shares and voting rights: November 30, 2025

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Nov 26, 2025, 12:30 PM EST - 10 days ago

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

PFE

Valneva to Further Consolidate its Operations in France

Nov 26, 2025, 11:30 AM EST - 10 days ago

Valneva to Further Consolidate its Operations in France

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Nov 26, 2025, 6:37 AM EST - 10 days ago

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Nov 26, 2025, 1:00 AM EST - 11 days ago

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Valneva SE (VALN) Q3 2025 Earnings Call Transcript

Nov 20, 2025, 3:23 PM EST - 16 days ago

Valneva SE (VALN) Q3 2025 Earnings Call Transcript

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Nov 20, 2025, 1:00 AM EST - 17 days ago

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Nov 4, 2025, 1:00 AM EST - 4 weeks ago

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Oct 27, 2025, 12:45 PM EDT - 5 weeks ago

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Oct 6, 2025, 11:35 AM EDT - 2 months ago

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Sep 30, 2025, 1:00 AM EDT - 2 months ago

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Sep 3, 2025, 1:00 AM EDT - 3 months ago

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

Aug 25, 2025, 12:02 PM EDT - 3 months ago

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

KDP VENU

Johnson Fistel Investigates Valneva Following FDA Suspension

Aug 25, 2025, 10:43 AM EDT - 3 months ago

Johnson Fistel Investigates Valneva Following FDA Suspension

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Aug 25, 2025, 10:29 AM EDT - 3 months ago

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Aug 25, 2025, 1:16 AM EDT - 3 months ago

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Aug 25, 2025, 1:00 AM EDT - 3 months ago

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Aug 18, 2025, 1:00 AM EDT - 3 months ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 3:20 PM EDT - 4 months ago

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 1:00 AM EDT - 4 months ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Aug 7, 2025, 1:18 AM EDT - 4 months ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Jul 29, 2025, 10:00 AM EDT - 4 months ago

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Jul 11, 2025, 11:35 AM EDT - 5 months ago

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Jul 11, 2025, 8:18 AM EDT - 5 months ago

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Jun 26, 2025, 1:00 AM EDT - 5 months ago

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

Jun 25, 2025, 11:45 AM EDT - 5 months ago

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Jun 9, 2025, 10:29 AM EDT - 6 months ago

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Jun 5, 2025, 11:45 AM EDT - 6 months ago

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Jun 4, 2025, 1:00 AM EDT - 6 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025, 11:30 AM EDT - 6 months ago

Valneva to Participate at U.S. and European Investor Conferences in June

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

May 12, 2025, 1:00 AM EDT - 7 months ago

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

May 9, 2025, 9:47 AM EDT - 7 months ago

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

May 8, 2025, 12:30 AM EDT - 7 months ago

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

May 7, 2025, 11:45 AM EDT - 7 months ago

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

May 7, 2025, 8:40 AM EDT - 7 months ago

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 7, 2025, 1:00 AM EDT - 7 months ago

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Apr 26, 2025, 1:10 PM EDT - 8 months ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Apr 18, 2025, 4:00 AM EDT - 8 months ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Apr 16, 2025, 11:45 AM EDT - 8 months ago

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Apr 14, 2025, 2:28 PM EDT - 8 months ago

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Apr 14, 2025, 11:45 AM EDT - 8 months ago

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Apr 9, 2025, 1:00 AM EDT - 8 months ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Apr 7, 2025, 9:33 AM EDT - 8 months ago

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Valneva SE Shareholding Declaration - March 2025

Apr 3, 2025, 11:45 AM EDT - 8 months ago

Valneva SE Shareholding Declaration - March 2025

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Apr 1, 2025, 11:45 AM EDT - 8 months ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Mar 31, 2025, 1:00 AM EDT - 8 months ago

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Mar 26, 2025, 1:00 PM EDT - 9 months ago

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

SuperGreenToday
SuperGreenToday Dec. 4 at 11:10 PM
$VALN
0 · Reply
Creisi
Creisi Dec. 3 at 3:07 PM
$VALN It's from France and positive news on foreign traded stocks simply don't hit the headlines in the USA like USA based companies do. Had Pfizer released this data, it would have exploded. Valneva need to do their Press Releases in partnership with Pfizer and the response will be 5x better. 45% of the world's investment market is the USA. Focus your PR news releases on the USA market and the impact is magnified. I've been around for over 30 years and have seen this scenario a 1000+ times for non USA companies.
0 · Reply
buzzkiller
buzzkiller Dec. 3 at 2:10 PM
$VALN that the market is continually rejecting any positive sp momentum tells me there is some sort of unspoken issue with this co. -- any guesses?
1 · Reply
BluePeakCapital
BluePeakCapital Dec. 2 at 2:41 PM
$VALN
0 · Reply
ajmore
ajmore Dec. 2 at 10:15 AM
$VALN pfizer's set back on the covid front due to myocarditis will leave them with no option but to acquire valneva for the covid vaccine. just a reminder, novavax vlp vaccine had issues with myocarditis too!
0 · Reply
buzzkiller
buzzkiller Dec. 1 at 11:07 AM
$VALN high school kids in Atlanta beating this company..
0 · Reply
Creisi
Creisi Nov. 30 at 7:37 PM
$VALN This vaccine is also effective against the Lone Star Tick which turns eating meat into a death sentence... this tick is also becoming prominent in the Southwest and as far up the coast as Maine... 2 weeks ago a NYC resident died after being bitten by a Lone Star Tick and then eating a hamburger. The market opportunity for a Lyme Disease Vaccine is a game changer and USA sales projections are grossly underestimated by analysts. Anyone that does anything outside is going to get this vaccine... it makes no sense not to. Virtually zero side effects and extremely protective. With Pfizer making a BLA submission in 2026 to market the Vaccine on VALNEVA's behalf, this little vaccine company will be bought by Pfizer by October 2026 or will report huge earnings by 2027 thrusting this stock price will into the $50-60 range either way.
1 · Reply
Siuolman58
Siuolman58 Nov. 29 at 9:44 AM
$VALN https://share.google/L2fPl3T5beSVlnffY
0 · Reply
Creisi
Creisi Nov. 28 at 1:14 PM
$VALN On track for the Lyme Disease Vaccine BLA in 2026 according to news reports in partnership with Pfizer. Expected $200,000,000 Annual Royaly Payments from Pfizer from the Lyme Vaccine alone. Strong Pfizer Buy Out rumours as Valneva consolidates operations in Lyon, France.
0 · Reply
Mac24Daddy
Mac24Daddy Nov. 26 at 4:04 PM
$VALN caution. Still trying to recoup from England, pulling the Covid vaccine and then the recent FDA removal of the next vaccine and now this. I’m really cautious at this point every time we look for a break out something comes up and throws a wrench in the works. Understandably, we can’t protect the outcomes, but this would be three for three if it hits the south side of where it’s supposed to go.
1 · Reply
ajmore
ajmore Nov. 26 at 11:30 AM
$VALN annual revenues from lyme vaccine expected to bring valneva royalties of ~200mln a year! thats alone worth 1.2 bln in discounted cash flow market cap!. at 4 Euros (8 usd for US listing), its a bargain!
0 · Reply
TedBaker08
TedBaker08 Nov. 26 at 10:13 AM
$VALN All positive things https://valneva.com/press-release/valneva-announces-positive-final-phase-2-results-for-lyme-disease-vaccine-candidate/
0 · Reply
mebanks
mebanks Nov. 26 at 9:25 AM
$VALN , watching closely; based on last QTR report "143.5 million euros in cash"/cash burn "Operating cash burn improved to 28.4 million euros", now with good Phase 2 data https://valneva.com/press-release/valneva-announces-positive-final-phase-2-results-for-lyme-disease-vaccine-candidate/ https://finance.yahoo.com/news/valneva-misses-revenue-estimates-reaffirms-111733381.html
0 · Reply
ajmore
ajmore Nov. 26 at 7:51 AM
$VALN https://valneva.com/press-release/valneva-announces-positive-final-phase-2-results-for-lyme-disease-vaccine-candidate/ pfizer will most likely swoop in and take the rest of the shares in anticipation of a positive phase 3 readout.
0 · Reply
ajmore
ajmore Nov. 26 at 7:22 AM
$VALN data out data out. Lyme vaccine Shows strong phase 2 booster results with favorable safety. this is important and as trial had 600 participants this enforces the fact that cumulatively this is significantly high and reduces any chances for an error. shorts cover! Buy.
0 · Reply
buzzkiller
buzzkiller Nov. 26 at 6:08 AM
$VALN time to fly
0 · Reply
Siuolman58
Siuolman58 Nov. 25 at 1:34 PM
$VALN The secret stock!!! It trades big in Europe so no worries. Just keep buying and waiting. Money in the bank.
0 · Reply
Creisi
Creisi Nov. 21 at 5:37 PM
$VALN Total volume 900 so far today. This has got to be the lowest volume stock listed. When the Phase 3 Lyme Disease data is released by Pfizer (VALNEVA's Partner); this stock is going to see a swelling of buying pressure which will catapult the price because of this incredibly low daily volume movement. Lyme Disease vaccine is going to be a tremendous catalyst for Valneva.
0 · Reply
TedBaker08
TedBaker08 Nov. 20 at 9:06 AM
$VALN https://valneva.com/press-release/valneva-reports-nine-month-2025-financial-results-and-provides-corporate-updates/
0 · Reply
buzzkiller
buzzkiller Nov. 14 at 7:34 PM
$VALN what a horrible experience this has been.
0 · Reply
Creisi
Creisi Nov. 5 at 3:34 PM
$VALN Only 687 shares were sold since the start of the day. That is the lowest trading volume of a 3/4 billion dollar company than I have ever seen. This clearly shows the price the market has for VALN stock is not reliable. Any news at all could make this stock gap up exponentially in a very short period of time.
1 · Reply
Creisi
Creisi Nov. 4 at 12:53 PM
$VALN Great news!
0 · Reply